PITUITARY ADENOMA

✓ Medically ReviewedDISEASEID: MDBT0278🚨 TRIAGE: URGENTICD-10: D35.2

📖

Definition

CLINICAL DEFINITION

Pituitary adenoma is a benign, typically monoclonal neoplasm arising from the hormone-producing cells of the anterior pituitary gland (adenohypophysis). Under the 2022 WHO classification, these lesions are formally designated pituitary neuroendocrine tumours (PitNETs) to reflect their neuroendocrine lineage, although the traditional term 'pituitary adenoma' remains widely used in clinical practice. They are classified by size as microadenomas (<10 mm) or macroadenomas (≥10 mm), and by functional status as secretory (hormone-secreting) or non-functioning. Clinical manifestations arise from hormone hypersecretion syndromes, mass effect on surrounding structures (particularly the optic chiasm and normal pituitary tissue), or both.

IN PLAIN ENGLISH

A pituitary adenoma is a benign (non-cancerous) growth in the pituitary gland, a small hormone-producing gland at the base of the brain. It can make too much of one hormone, or it can grow large enough to press on nearby nerves and normal pituitary tissue, causing vision problems and hormone deficiencies. Most are slow-growing and treatable.

COMMON MISCONCEPTION / WHAT IT DOES NOT MEAN

Pituitary adenoma is NOT a malignant brain tumour in the conventional sense; the vast majority are benign and do not metastasise. It is also NOT synonymous with pituitary carcinoma, which is diagnosed only in the presence of cerebrospinal fluid or systemic metastasis and accounts for less than 0.2% of pituitary tumours. Additionally, a pituitary adenoma is not the same as a pituitary incidentaloma (an imaging-detected lesion without clinical manifestations), although an incidentaloma may subsequently prove to be an adenoma.

🔤

Word Breakdown

pituit-

=pituitary (from Latin 'pituita' — phlegm, based on the historical belief that the gland secreted phlegm)

-ary

=-ary (pertaining to); aden- (gland) + -oma (tumour, swelling)

Literal Meaning: Pertaining to the pituitary gland; combined with 'adenoma', meaning a benign glandular tumour of the pituitary.

🏷️

Abbreviations

PA=Pituitary Adenoma — the traditional term for a benign neoplasm of the anterior pituitary, now classified as a PitNET under WHO 2022 nomenclature

PitNET=Pituitary Neuroendocrine Tumour — the 2022 WHO classification term for tumours arising from anterior pituitary neuroendocrine cells, replacing 'pituitary adenoma' in formal pathological nomenclature

NFPA=Non-Functioning Pituitary Adenoma — a pituitary tumour without clinically significant hormone hypersecretion, often presenting with mass effect

🔄

Synonyms & Variants

Pituitary Neuroendocrine Tumour (PitNET)›Benign Pituitary Neoplasm›

🎯

Category-Specific Context

As a Disease, pituitary adenoma represents a defined pathological entity with recognised diagnostic criteria based on imaging, hormonal evaluation, and, where applicable, histopathology. The clinical spectrum ranges from small, hormonally silent microadenomas detected incidentally to large, invasive macroadenomas causing optic chiasm compression and panhypopituitarism. Classification by size (microadenoma versus macroadenoma) and functional status (functioning versus non-functioning) underpins both prognostic stratification and therapeutic decision-making.

🏥

Clinical Context & Usage

CLINICAL SETTINGS

Endocrinology Outpatient ClinicNeurosurgery WardGeneral Medicine WardOphthalmology ClinicEmergency DepartmentRadiology Department

USAGE & DOCUMENTATION NOTES

In clinical documentation, the term is commonly abbreviated as 'PA' or, increasingly, 'PitNET'. Notes typically specify size ('microadenoma' or 'macroadenoma') and functional status ('prolactin-secreting', 'non-functioning'). Referral letters to neurosurgery frequently describe suprasellar extension and optic chiasm contact. Endocrine clinic notes record serial prolactin, IGF-1, and 9 am cortisol values alongside visual field results. Postoperative notes distinguish 'gross total resection' from 'subtotal resection with residual tumour', and surveillance imaging intervals are documented in months.

🔬

Primary Causes & Pathophysiology

PATHOPHYSIOLOGY

Pituitary adenomas arise from clonal expansion of a single anterior pituitary cell lineage, driven by somatic or germline genetic alterations that dysregulate cell-cycle control and hormone secretion. Activating somatic mutations in GNAS (encoding the Gsα subunit) are characteristic of somatotroph adenomas, while USP8 mutations are found in a subset of corticotroph adenomas; germline mutations in MEN1, AIP, and other genes underlie familial forms. As the adenoma expands within the confined sella turcica, it compresses the normal anterior pituitary gland and may impair hypothalamic–pituitary portal blood flow, producing hypopituitarism. Suprasellar extension compresses the optic chiasm, classically causing bitemporal hemianopia. Additionally, stalk compression disrupts dopamine-mediated tonic inhibition of prolactin secretion (the 'stalk effect'), producing mild hyperprolactinaemia even in non-lactotroph tumours. Hormone-secreting adenomas produce their respective hypersecretion syndromes independently of normal hypothalamic regulation.

PRIMARY CAUSES

Sporadic somatic mutations

Acquired genetic alterations in pituitary cells (e.g., GNAS in somatotroph adenomas, USP8 in corticotroph adenomas) activate proliferative and secretory pathways, leading to clonal expansion.

Multiple Endocrine Neoplasia type 1 (MEN1)

Germline loss-of-function mutations in the MEN1 tumour suppressor gene predispose to pituitary adenomas (most commonly prolactinomas), often alongside parathyroid and pancreatic neuroendocrine tumours.

Familial Isolated Pituitary Adenoma (FIPA)

Germline mutations, most commonly in the AIP gene, cause familial pituitary adenomas without other syndromic features, typically presenting at a younger age with GH-secreting or prolactin-secreting tumours.

Carney Complex

Inactivating mutations in PRKAR1A lead to constitutive protein kinase A activation and predispose to GH-secreting pituitary adenomas, along with cardiac myxomas and spotty skin pigmentation.

🌍

Epidemiology

Prevalence:Pituitary adenomas account for approximately 10–15% of intracranial tumours. Clinically relevant adenomas have an estimated prevalence of approximately 80–90 cases per 100,000 individuals in the general population; autopsy and imaging studies detect incidental pituitary lesions in up to 10–25% of unselected individuals.

Age Group:Pituitary adenomas can occur at any age but are most frequently diagnosed in adults aged 35–60 years. Prolactinomas peak in the second to fifth decades, whereas non-functioning adenomas are more commonly diagnosed in the fourth to eighth decades. Paediatric cases are less common and are enriched for genetically driven tumours.

Sex Predilection:Equal

Geographic Distribution:Pituitary adenomas occur worldwide without strong geographic restriction. Slight differences in subtype distribution and age at presentation have been reported across populations, but no consistent region-specific pattern is established for the entity as a whole.

Red Flags & Triage ★

TRIAGE LEVEL

🚨 URGENT

DO NOT MISS — LIFE-THREATENING PRESENTATIONS

A patient with a known pituitary adenoma presenting with sudden severe headache, visual loss, or altered consciousness may have pituitary apoplexy; this requires urgent neuroimaging and corticosteroid administration because it can be life-threatening.
New bitemporal visual field loss in a patient with a macroadenoma suggests optic chiasm compression and warrants urgent neuro-ophthalmological and neurosurgical assessment to prevent irreversible visual loss.
Hyponatraemia or unexplained hypotension in a patient with a pituitary mass should raise concern for hypocortisolism (adrenal insufficiency) and prompt immediate glucocorticoid assessment and treatment.

URGENT EVALUATION TRIGGERS

Sudden-onset severe headache ('thunderclap') in a patient with a known pituitary adenoma
Acute visual deterioration or new visual field defect
Haemodynamic instability or unexplained hypotension with a pituitary mass
Altered consciousness or new cranial nerve palsy in a patient with a sellar lesion

Contraindications & Precautions

CONTRAINDICATIONS

Dopamine agonist therapy is contraindicated in asymptomatic prolactinomas without a clear indication for treatment
because of potential adverse effects without established benefit in this subgroup.
Transsphenoidal surgery is relatively contraindicated in patients with severe uncorrectable coagulopathy or untreated severe medical instability until the underlying condition is optimised.
Radiotherapy is contraindicated during pregnancy and should be avoided in patients with certain genetic tumour syndromes where second-malignancy risk is a concern
pending specialist assessment.

SPECIAL PRECAUTIONS

Before surgery for pituitary adenoma
screen for and treat hypocortisolism; undiagnosed adrenal insufficiency can precipitate adrenal crisis during the perioperative period.
In patients with macroadenomas and visual field defects
arrange formal neuro-ophthalmological assessment and counsel on the urgency of reporting further visual deterioration.
When interpreting serum prolactin in a patient with a large pituitary mass
distinguish true prolactinoma from stalk-effect hyperprolactinaemia to avoid inappropriate dopamine agonist therapy for a non-functioning tumour.
Use caution when initiating dopamine agonists in patients with a history of impulse-control disorders or cardiac valvulopathy
and monitor accordingly.

Complications

DOWNSTREAM CLINICAL COMPLICATIONS

Hypopituitarism — compression of normal anterior pituitary tissue
leading to deficiency of one or more pituitary hormones (most commonly GH and gonadotropins)
Bitemporal hemianopia — suprasellar extension compressing the optic chiasm
with risk of permanent visual loss if decompression is delayed
Pituitary apoplexy — acute haemorrhage or infarction within the adenoma
presenting as a neuroendocrine emergency with severe headache
visual deterioration
and haemodynamic compromise
Cavernous sinus invasion — extension into the cavernous sinus with potential cranial nerve palsies (III
IV
V1
V2
VI)
CSF rhinorrhoea — a postoperative complication of transsphenoidal surgery
carrying a risk of meningitis

🔀

Confused With (LASA & DDx) ★

LEXICAL (LASA) — SIMILAR NAMES

Pituitary Apoplexy

Shares the word 'pituitary' and is easily confused in rapid clinical communication; apoplexy denotes acute haemorrhage/infarction within an adenoma, not the adenoma itself.

Pituitary Incidentaloma

Sounds similar and both refer to pituitary masses; an incidentaloma is an imaging-detected lesion without attributable clinical manifestations, whereas an adenoma is a defined neoplasm that may or may not be functioning.

CLINICAL DIFFERENTIAL DIAGNOSES (DDx)

Craniopharyngioma

Key Distinguishing Feature: Typically calcified on CT, often cystic, and arises from remnants of Rathke's pouch; usually causes hypopituitarism and visual field defects but does not produce the characteristic hormone hypersecretion syndromes of functioning pituitary adenomas.

Sellar Meningioma

Key Distinguishing Feature: Arises from the dura of the sellar tubercle or diaphragma sellae, often hyperdense and enhancing on imaging; does not typically cause hormone hypersecretion, and the normal pituitary gland is displaced inferiorly rather than superiorly.

Rathke Cleft Cyst

Key Distinguishing Feature: A benign cystic lesion that is usually non-enhancing and does not cause hormone hypersecretion; may mimic a cystic macroadenoma on imaging but lacks the solid enhancing component and functional endocrine features of an adenoma.

Lymphocytic Hypophysitis

Key Distinguishing Feature: An inflammatory condition, often pregnancy-related, presenting with hypopituitarism and a diffusely enlarged pituitary stalk; imaging shows stalk thickening and homogeneous enhancement without a discrete adenoma.

💎

Clinical Pearls

💎

The 'stalk effect' explains mild hyperprolactinaemia (typically <200 ng/mL) in patients with non-functioning macroadenomas; this is caused by compression of the pituitary stalk disrupting dopamine inhibition, and it should not be mistaken for a true prolactinoma, which usually produces much higher prolactin levels.

💎

Bitemporal hemianopia is the classic visual field defect of a pituitary macroadenoma because the optic chiasm contains crossing nasal retinal fibres that subserve the temporal visual fields; formal perimetry is essential when the tumour abuts the chiasm.

💎

Pituitary apoplexy can be the first presentation of a previously undiagnosed adenoma, and the classic triad of sudden headache, visual disturbance, and altered consciousness should prompt immediate glucocorticoid therapy before imaging results are available if adrenal crisis is suspected.

💎

In patients with acromegaly, IGF-1 is the preferred biochemical screening test because GH secretion is pulsatile and a random GH level can be misleading; elevated IGF-1 should prompt an oral glucose tolerance test with GH suppression for confirmation.

💎

Prolactinomas are the most common functioning pituitary adenomas and are usually treated first-line with dopamine agonists (cabergoline or bromocriptine); surgery is reserved for resistance, intolerance, or specific patient preferences.

📝

Example Usage & SOAP

CLINICAL SENTENCE

"MRI pituitary with contrast demonstrated a 14 mm macroadenoma with suprasellar extension abutting the optic chiasm; serum prolactin was 45 ng/mL, consistent with a stalk effect rather than a true prolactinoma, and formal visual fields showed a mild bitemporal superior quadrantanopia."

IN A SOAP NOTE

S: A 42-year-old woman reports 12 months of secondary amenorrhoea and new peripheral visual difficulty. O: Serum prolactin 1,850 mIU/L; MRI pituitary shows a 9 mm left-sided pituitary microadenoma with no suprasellar extension; visual fields full to confrontation. A: Prolactin-secreting pituitary microadenoma (prolactinoma). P: Initiate cabergoline 0.25 mg twice weekly; repeat prolactin in 4–6 weeks; neuro-ophthalmology review if visual symptoms progress.

DIFFERENTIAL DIAGNOSIS CONTEXT

Differential for a sellar mass with visual field compromise: (1) Pituitary macroadenoma — typically causes bitemporal hemianopia and may be functioning or non-functioning; (2) Craniopharyngioma — often calcified and cystic, with prominent hypopituitarism; (3) Sellar meningioma — dural-based, hyperdense, and does not usually cause hormone hypersecretion; (4) Lymphocytic hypophysitis — diffuse stalk thickening with hypopituitarism, often pregnancy-related. Dedicated pituitary MRI with contrast and a full hormone panel distinguish these entities.

📊

Classifications & Scoring

SCORING TOOL

Knosp Classification

Grades cavernous sinus invasion of pituitary adenomas on MRI by assessing the relationship of the tumour to the internal carotid artery; grades 0–2 indicate no or mild invasion, while grades 3–4 indicate likely invasion, influencing surgical strategy.

Clinical Calculator ↗

📈

Prognosis

SHORT-TERM OUTCOME

Short-term prognosis depends on tumour type and presentation. Prolactinomas typically respond well to dopamine agonist therapy with normalisation of prolactin and tumour shrinkage over weeks to months. Non-functioning macroadenomas with visual field compromise require timely surgical decompression; visual improvement is observed in a substantial proportion of patients, though recovery may be incomplete if compression has been prolonged. Pituitary apoplexy carries short-term risk of adrenal crisis and visual loss without prompt glucocorticoid replacement and, where indicated, surgical decompression.

LONG-TERM PROGNOSIS

Long-term prognosis for most pituitary adenomas is favourable, with disease-specific mortality low for prolactinomas and non-functioning adenomas managed appropriately. However, recurrence or progression occurs in a minority of patients after surgery (reported in approximately 10–20% of non-functioning adenomas over several years), and lifelong surveillance is often required. Hormone-secreting adenomas that remain uncontrolled (e.g., refractory Cushing's disease or acromegaly) carry increased cardiovascular and metabolic morbidity and elevated standardised mortality ratios. Hypopituitarism, when present, requires lifelong hormone replacement.

📚

References & Coding

ICD-10 DIAGNOSTIC CODE

D35.2

LITERATURE CITATIONS & GUIDELINES

[1]WHO Classification of Tumours Editorial Board. Endocrine and Neuroendocrine Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2022.

[2]Fleseriu M, et al. Pituitary incidentaloma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2023;108(9):2139-2186.

[3]Petersenn S, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international consensus statement. Nat Rev Endocrinol. 2023;19(12):722-740.

[4]Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA. 2017;317(5):516-524.

MEDICAL DISCLAIMER — This content is intended for educational purposes and qualified healthcare professionals only. Always refer to current clinical diagnostic criteria, institutional protocols, and official guidelines. Medobo is not responsible for clinical decisions made based on this content.